Clicky

ImmunoGen, Inc.(IMGN)

Description: ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.


Keywords: Biotechnology Clinical Medicine Drugs Solid Tumors Breast Cancer Monoclonal Antibodies Lymphoma Non Small Cell Lung Cancer Ovarian Cancer Multiple Myeloma Small Cell Lung Cancer Medical Research Treatment Of Breast Cancer Hematological Malignancies Antibody Drug Conjugate Chronic Lymphocytic Leukemia Cancer Therapeutics Acute Lymphoblastic Leukemia Her2 Clinical Trial Product Lymphocytic Leukemia Metastatic Breast Cancer Immunogen B Cell Acute Lymphoblastic Leukemia Mesothelin Treatment Of Non Hodgkin's Lymphoma Trastuzumab Emtansine

Home Page: www.immunogen.com

IMGN Technical Analysis

830 Winter Street
Waltham, MA 02451-1477
United States
Phone: 781 895 0600


Officers

Name Title
Mr. Mark Joseph Enyedy Pres, CEO & Director
Ms. Susan Altschuller Ph.D. Sr. VP & CFO
Dr. Anna Berkenblit M.D., MM.Sc Sr. VP & Chief Medical Officer
Ms. Stacy A. Coen Sr. VP & Chief Bus. Officer
Ms. Renee Lentini VP of Fin. & Principal Accounting Officer
Ms. Courtney O'Konek Sr. Director of Corp. Communications & Investor Relations
Mr. Daniel S. Char J.D. Sr. VP & Chief Legal Officer
Ms. Audrey Bergan Sr. VP & Chief HR Officer
Dr. Theresa G. Wingrove Sr. VP of Regulatory Affairs & Quality
Dr. Mary Margaret Huizinga FACP, M.D., M.P.H. Sr. VP & Head of Medical Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 6.4114
Price-to-Sales TTM: 11.4754
IPO Date: 1989-11-16
Fiscal Year End: December
Full Time Employees: 106
Back to stocks